Provided by Tiger Trade Technology Pte. Ltd.

Tango Therapeutics Inc.

23.89
-0.6500-2.65%
Post-market: 23.50-0.3900-1.63%16:57 EDT
Volume:1.79M
Turnover:42.79M
Market Cap:4.04B
PE:-28.44
High:24.55
Open:24.55
Low:23.59
Close:24.54
52wk High:34.39
52wk Low:6.69
Shares:169.00M
Float Shares:142.96M
Volume Ratio:0.60
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8400
EPS(LYR):-0.8746
ROE:-21.34%
ROA:-12.99%
PB:3.94
PE(LYR):-27.32

Loading ...

Aug 30, 2023

Major Issues Report

Form 8-K - Current report
Aug 22, 2023

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Aug 17, 2023

Beneficial Ownership Change

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Aug 10, 2023

Major Issues Report

Form 8-K - Current report
Aug 07, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 07, 2023

Major Issues Report

Form 8-K - Current report
Jun 07, 2023

Major Issues Report

Form 8-K - Current report
May 09, 2023

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 09, 2023

Major Issues Report

8-K - Current report
Mar 27, 2023

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 27, 2023

Major Issues Report

8-K - Current report
Feb 28, 2023

Major Issues Report

8-K - Current report
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 07, 2023

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Nov 10, 2022

Major Issues Report

8-K - Current report
Nov 10, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Sep 08, 2022

Correspondence

CORRESP [Cover] - Correspondence
Aug 10, 2022

Major Issues Report

8-K - Current report
Aug 10, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]